RT Journal Article
SR Electronic
T1 COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.01.20087494
DO 10.1101/2020.05.01.20087494
A1 da Rocha, Aline Pereira
A1 Atallah, Alvaro Nagib
A1 Pinto, Ana Carolina Pereira Nunes
A1 Rocha-Filho, César Ramos
A1 de Assis Reis, Felipe Sebastião
A1 Milby, Keilla Martins
A1 Civile, Vinicius Tassoni
A1 Carvas Junior, Nelson
A1 Santos, Rodolfo Rodrigo Pereira
A1 Ferla, Laura Jantsch
A1 Trevisani, Giulia Fernandes Moça
A1 Ramalho, Gabriel Sodré
A1 Puga, Maria Eduarda Santos
A1 Trevisani, Virgínia Fernandes Moça
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087494.abstract
AB CONTEXT AND OBJECTIVE We propose to systematically review the available evidence to evaluate if patients with immune mediated inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, Disease-Modifying Anti-Rheumatic Drugs (DMARD) or targeted synthetic DMARDs have better or worse outcomes when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCRD42020179863Funding StatementThis study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior‐Brasil (CAPES)‐ Finance Code 001Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article